Biomarkers of diabetic nephropathy, the present and the future

Current Diabetes Reviews

Volumn 8, Issue 5, 2012, Pages 317-328

  Jim, Belinda ^a   Santos, Jolina ^a   Spath, Fuad ^a   He, John Cijiang ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Biomarker; Diabetes; Diabetic Nephropathy; Genomics; Metabolomics; Nephrin; Podocyte; Proteomics; Transcriptomics

Indexed keywords

ADIPONECTIN; ALBUMIN; AMINOACYLHISTIDINE DIPEPTIDASE; BIOLOGICAL MARKER; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 23; FIBRONECTIN; GLUCOSE TRANSPORTER 1; KIDNEY INJURY MOLECULE 1; MESSENGER RNA; MYELOPEROXIDASE; N ACETYL BETA GLUCOSAMINIDASE; NEPHRIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NOTCH RECEPTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PODOCALYXIN; PODOCIN; PROTEIN; SYNAPTOPODIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DNA MICROARRAY; ENVIRONMENTAL FACTOR; EPIGENETICS; FALSE POSITIVE RESULT; FOCAL GLOMERULOSCLEROSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOMICS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEREDITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; METABOLISM; METABOLOMICS; NEPHRON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PODOCYTE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SERIAL ANALYSIS OF GENE EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; TREATMENT RESPONSE; URINALYSIS;

ADIPONECTIN; ALBUMINURIA; BIOLOGICAL MARKERS; COLLAGEN TYPE IV; CYSTATIN C; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PODOCYTES; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RNA, MESSENGER;

EID: 84866658486     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912802083478     Document Type: Review

References (129)

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetickidney disease in the United States. JAMA. 2011; 305(24): 2532-9. Epub 2011/06/23.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications ofthe diabetes epidemic. Nature. 2001; 414(6865): 782-7. Epub2001/12/14.
3. Molitch ME, DeFronzo RA, Franz MJ, et al. Diabetic nephropathy. Diabetes Care. 2003; 26 Suppl 1: S94-8. Epub 2002/12/28.
4. Granier C, Makni K, Molina L, Jardin-Watelet B, Ayadi H, JarrayaF. Gene and protein markers of diabetic nephropathy. Nephrol DialTransplant. 2008; 23(3): 792-9. Epub 2007/12/11.
5. Mogensen CE. Microalbuminuria predicts clinical proteinuria andearly mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6): 356-60. Epub 1984/02/09.
6. Mogensen CE, Christensen CK. Predicting diabetic nephropathy ininsulin-dependent patients. N Engl J Med. 1984; 311(2): 89-93. Epub 1984/07/12.
7. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy ininsulin-dependent diabetes mellitus. Lancet. 1982; 1(8287): 1430-2. Epub 1982/06/26.
8. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. Aprospective population-based study of microalbuminuria as apredictor of mortality in NIDDM. Diabetes Care. 1993; 16(7): 996-1003. Epub 1993/07/01.
9. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes:the importance of early renal function decline. Curr Opin NephrolHypertens. 2009; 18(3): 233-40. Epub 2009/03/21.
10. Karalliedde J, Viberti G. Proteinuria in diabetes: bystander orpathway to cardiorenal disease? J Am Soc Nephrol. 2010; 21(12):2020-7. Epub 2010/11/06.
11. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease-dependent mechanisms of albuminuria. Am J PhysiolRenal Physiol. 2008; 295(6): F1589-600. Epub 2008/06/27.
12. Kalansooriya A, Holbrook I, Jennings P, Whiting PH. Serumcystatin C, enzymuria, tubular proteinuria and early renal insult intype 2 diabetes. British journal of biomedical science. 2007; 64(3):121-3. Epub 2007/10/04.
13. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renalfunction decline in patients with diabetes and normal or elevatedGFR by serial measurements of serum cystatin C concentration:results of a 4-year follow-up study. J Am Soc Nephrol. 2005;16(5): 1404-12. Epub 2005/03/25.
14. Yagame M, Kim Y, Zhu D, et al. Differential distribution of typeIV collagen chains in patients with diabetic nephropathy in noninsulin-dependent diabetes mellitus. Nephron. 1995; 70(1): 42-8. Epub 1995/01/01.
15. Kotajima N, Kimura T, Kanda T, et al. Type IV collagen as anearly marker for diabetic nephropathy in non-insulin-dependentdiabetes mellitus. Journal of diabetes and its complications. 2000;14(1): 13-7. Epub 2000/08/05.
16. Kado S, Aoki A, Wada S, et al. Urinary type IV collagen as amarker for early diabetic nephropathy. Diabetes research andclinical practice. 1996; 31(1-3): 103-8. Epub 1996/03/01.
17. Tomino Y, Suzuki S, Azushima C, et al. Asian multicenter trialson urinary type IV collagen in patients with diabetic nephropathy. Journal of clinical laboratory analysis. 2001; 15(4): 188-92. Epub2001/07/04.
18. Morita M, Uchigata Y, Hanai K, Ogawa Y, Iwamoto Y. Association of urinary type IV collagen with GFR decline in youngpatients with type 1 diabetes. Am J Kidney Dis. 2011; 58(6): 915-20. Epub 2011/07/19.
19. Araki S, Haneda M, Koya D, et al. Association between urinarytype IV collagen level and deterioration of renal function in type 2diabetic patients without overt proteinuria. Diabetes Care. 2010;33(8): 1805-10. Epub 2010/07/30.
20. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes & metabolism. 2012. Epub 2012/01/19.
21. Barlovic DP, Zaletel J, Prezelj J. Adipocytokines are associatedwith renal function in patients with normal range glomerularfiltration rate and type 2 diabetes. Cytokine. 2009; 46(1): 142-5. Epub 2009/02/19.
22. Fujita H, Morii T, Koshimura J, et al. Possible relationshipbetween adiponectin and renal tubular injury in diabeticnephropathy. Endocrine journal. 2006; 53(6): 745-52. Epub2006/09/13.
23. Titan SM, Zatz R, Graciolli FG, et al. FGF-23 as a predictor ofrenal outcome in diabetic nephropathy. Clin J Am Soc Nephrol.2011; 6(2): 241-7. Epub 2010/10/23.
24. Gohda T, Niewczas MA, Ficociello LH, et al. Circulating TNFReceptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. J AmSoc Nephrol. 2012. Epub 2012/01/24.
25. Niewczas MA, Gohda T, Skupien J, et al. Circulating TNFReceptors 1 and 2 Predict ESRD in Type 2 Diabetes. J Am SocNephrol. 2012. Epub 2012/01/24.
26. Al-Lamki RS, Wang J, Vandenabeele P, et al. TNFR1-andTNFR2-mediated signaling pathways in human kidney are celltype-specific and differentially contribute to renal injury. FASEB J.2005; 19(12): 1637-45. Epub 2005/10/01.
27. Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNFreceptor 2, not receptor 1, is essential for the development ofglomerulonephritis. J Clin Invest. 2005; 115(5): 1199-209. Epub2005/04/21.
28. Thomas MC, Burns WC, Cooper ME. Tubular changes in earlydiabetic nephropathy. Advances in chronic kidney disease. 2005;12(2): 177-86. Epub 2005/04/12.
29. Han WK, Wagener G, Zhu Y, Wang S, Lee HT. Urinarybiomarkers in the early detection of acute kidney injury aftercardiac surgery. Clin J Am Soc Nephrol. 2009; 4(5): 873-82. Epub2009/05/02.
30. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-FielitzA, Group NM-aI. Accuracy of neutrophil gelatinase-associatedlipocalin (NGAL) in diagnosis and prognosis in acute kidneyinjury: a systematic review and meta-analysis. Am J Kidney Dis.2009; 54(6): 1012-24. Epub 2009/10/24.
31. Bagshaw SM, Bellomo R. Early diagnosis of acute kidney injury. Current opinion in critical care. 2007; 13(6): 638-44. Epub2007/11/03.
32. Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubulardamage markers are elevated in patients with diabetes. DiabetesCare. 2011; 34(4): 975-81. Epub 2011/02/11.
33. Koh KT, Chia KS, Tan C. Proteinuria and enzymuria in noninsulin-dependent diabetics. Diabetes research and clinical practice.1993; 20(3): 215-21. Epub 1993/06/01.
34. Lapsley M, Flynn FV, Sansom PA. Beta 2-glycoprotein-1(apolipoprotein H) excretion and renal tubular malfunction indiabetic patients without clinical proteinuria. Journal of clinicalpathology. 1993; 46(5): 465-9. Epub 1993/05/01.
35. Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, RossingP. Tubular markers do not predict the decline in glomerularfiltration rate in type 1 diabetic patients with overt nephropathy. Kidney Int. 2011; 79(10): 1113-8. Epub 2011/01/29.
36. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-type fatty acid-binding protein predicts progression tonephropathy in type 1 diabetic patients. Diabetes Care. 2010;33(6): 1320-4. Epub 2010/02/27.
37. Kamijo-Ikemori A, Sugaya T, Yasuda T, et al. Clinicalsignificance of urinary liver-type fatty acid-binding protein indiabetic nephropathy of type 2 diabetic patients. Diabetes Care.2011; 34(3): 691-6. Epub 2011/01/29.
38. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cellnumber in normal subjects and in type 1 diabetic patients. KidneyInt. 2001; 59(6): 2104-13. Epub 2001/05/31.
39. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte lossand progressive glomerular injury in type II diabetes. J Clin Invest.1997; 99(2): 342-8. Epub 1997/01/15.
40. Meyer TW, Bennett PH, Nelson RG. Podocyte number predictslong-term urinary albumin excretion in Pima Indians with Type IIdiabetes and microalbuminuria. Diabetologia. 1999; 42(11): 1341-4. Epub 1999/11/07.
41. Shankland SJ. The podocyte's response to injury: role inproteinuria and glomerulosclerosis. Kidney Int. 2006; 69(12):2131-47. Epub 2006/05/12.
42. Nakamura T, Ushiyama C, Suzuki S, et al. Urinary excretion ofpodocytes in patients with diabetic nephropathy. Nephrol DialTransplant. 2000; 15(9): 1379-83. Epub 2000/09/09.
43. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinaryexcretion of viable podocytes in health and renal disease. Am JPhysiol Renal Physiol. 2003; 285(1): F40-8. Epub 2003/03/13.
44. Skoberne A, Konieczny A, Schiffer M. Glomerular epithelial cellsin the urine: what has to be done to make them worthwhile? Am JPhysiol Renal Physiol. 2009; 296(2): F230-41. Epub 2008/10/10.
45. Miettinen A, Solin ML, Reivinen J, Juvonen E, Vaisanen R, Holthofer H. Podocalyxin in rat platelets and megakaryocytes. AmJ Pathol. 1999; 154(3): 813-22. Epub 1999/03/18.
46. Kerjaschki D, Sharkey DJ, Farquhar MG. Identification andcharacterization of podocalyxin--the major sialoprotein of the renalglomerular epithelial cell. The Journal of cell biology. 1984; 98(4):1591-6. Epub 1984/04/01.
47. Achenbach J, Mengel M, Tossidou I, et al. Parietal epithelia cellsin the urine as a marker of disease activity in glomerular diseases. Nephrol Dial Transplant. 2008; 23(10): 3138-45. Epub 2008/05/07.
48. Kerosuo L, Juvonen E, Alitalo R, Gylling M, Kerjaschki D, Miettinen A. Podocalyxin in human haematopoietic cells. Britishjournal of haematology. 2004; 124(6): 809-18. Epub 2004/03/11.
49. Patari A, Forsblom C, Havana M, Taipale H, Groop PH, HolthoferH. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes. 2003; 52(12): 2969-74. Epub 2003/11/25.
50. Ng DP, Tai BC, Tan E, et al. Nephrinuria associates with multiplerenal traits in type 2 diabetes. Nephrol Dial Transplant. 2011;26(8): 2508-14. Epub 2011/01/05.
51. Wang G, Lai FM, Lai KB, Chow KM, Li KT, Szeto CC. Messenger RNA expression of podocyte-associated molecules inthe urinary sediment of patients with diabetic nephropathy. Nephron Clin Pract. 2007; 106(4): c169-79. Epub 2007/06/29.
52. Zheng M, Lv LL, Ni J, et al. Urinary podocyte-associated mRNAprofile in various stages of diabetic nephropathy. PLoS One. 2011;6(5): e20431. Epub 2011/06/10.
53. Camici M. Urinary biomarkers of podocyte injury. Biomark Med.2008; 2(6): 613-6. Epub 2008/12/01.
54. Sakairi T, Abe Y, Kajiyama H, et al. Conditionally immortalizedhuman podocyte cell lines established from urine. Am J PhysiolRenal Physiol. 2010; 298(3): F557-67. Epub 2009/12/04.
55. Jim B, Ghanta M, Qipo A, et al. Dysregulated nephrin in diabeticnephropathy of type 2 diabetes: a cross sectional study. PLoS One.2012; 7(5): e36041. Epub 2012/05/23.
56. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering ofdiabetic kidney disease. Evidence for genetic susceptibility todiabetic nephropathy. N Engl J Med. 1989; 320(18): 1161-5. Epub1989/05/04.
57. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insuredpopulation. JAMA. 2002; 287(19): 2519-27. Epub 2002/05/22.
58. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Geneticfactors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007;2(6): 1306-16. Epub 2007/10/19.
59. Boright AP, Paterson AD, Mirea L, et al. Genetic variation at theACE gene is associated with persistent microalbuminuria andsevere nephropathy in type 1 diabetes: the DCCT/EDIC GeneticsStudy. Diabetes. 2005; 54(4): 1238-44. Epub 2005/03/29.
60. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E, Mellitus S. Peroxisome proliferator-activated receptorgamma2polymorphism Pro12Ala is associated with nephropathyin type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes. 2002; 51(8): 2653-7. Epub 2002/07/30.
61. Caramori ML, Canani LH, Costa LA, Gross JL. The humanperoxisome proliferator-activated receptor gamma2(PPARgamma2) Pro12Ala polymorphism is associated withdecreased risk of diabetic nephropathy in patients with type 2diabetes. Diabetes. 2003; 52(12): 3010-3. Epub 2003/11/25.
62. Zintzaras E, Stefanidis I. Association between the GLUT1 genepolymorphism and the risk of diabetic nephropathy: a metaanalysis. Journal of human genetics. 2005; 50(2): 84-91. Epub2005/02/01.
63. Janssen B, Hohenadel D, Brinkkoetter P, et al. Carnosine as aprotective factor in diabetic nephropathy: association with a leucinerepeat of the carnosinase gene CNDP1. Diabetes. 2005; 54(8):2320-7. Epub 2005/07/28.
64. Ma RC, Tam CH, Wang Y, et al. Genetic variants of the proteinkinase C-beta 1 gene and development of end-stage renal disease inpatients with type 2 diabetes. JAMA. 2010; 304(8): 881-9. Epub2010/08/26.
65. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effectrisk gene for focal segmental glomerulosclerosis. Nature genetics.2008; 40(10): 1175-84. Epub 2008/09/17.
66. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated withnondiabetic end-stage renal disease in African Americans. Naturegenetics. 2008; 40(10): 1185-92. Epub 2008/09/17.
67. Genovese G, Friedman DJ, Ross MD, et al. Association oftrypanolytic ApoL1 variants with kidney disease in AfricanAmericans. Science. 2010; 329(5993): 841-5. Epub 2010/07/22.
68. Freedman BI, Langefeld CD, Lu L, et al. Differential effects ofMYH9 and APOL1 risk variants on FRMD3 Association withDiabetic ESRD in African Americans. PLoS genetics. 2011; 7(6):e1002150. Epub 2011/06/24.
69. Maeda S, Araki S, Babazono T, et al. Replication study for theassociation between four Loci identified by a genome-wideassociation study on European American subjects with type 1diabetes and susceptibility to diabetic nephropathy in Japanesesubjects with type 2 diabetes. Diabetes. 2010; 59(8): 2075-9. Epub2010/05/13.
70. Cooke JN, Bostrom MA, Hicks PJ, et al. Polymorphisms in MYH9are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant. 2011. Epub 2011/10/05.
71. Family Investigation of N, Diabetes Research G. Geneticdeterminants of diabetic nephropathy: The family investigation ofnephropathy and diabetes (FIND). J Am Soc Nephrol. 2003; 14(7Suppl 2): S202-4. Epub 2003/06/24.
72. Schelling JR, Abboud HE, Nicholas SB, et al. Genome-wide scanfor estimated glomerular filtration rate in multi-ethnic diabeticpopulations: the Family Investigation of Nephropathy and Diabetes(FIND). Diabetes. 2008; 57(1): 235-43. Epub 2007/11/16.
73. Iyengar SK, Abboud HE, Goddard KA, et al. Genome-wide scansfor diabetic nephropathy and albuminuria in multiethnicpopulations: the family investigation of nephropathy and diabetes(FIND). Diabetes. 2007; 56(6): 1577-85. Epub 2007/03/17.
74. Igo RP, Jr, Iyengar SK, Nicholas SB, et al. Genomewide linkagescan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol. 2011; 33(5): 381-9. Epub 2011/04/02.
75. Mueller PW, Rogus JJ, Cleary PA, et al. Genetics of Kidneys inDiabetes (GoKinD) study: a genetics collection available foridentifying genetic susceptibility factors for diabetic nephropathyin type 1 diabetes. J Am Soc Nephrol. 2006; 17(7): 1782-90. Epub2006/06/16.
76. Pezzolesi MG, Poznik GD, Mychaleckyj JC, et al. Genome-wideassociation scan for diabetic nephropathy susceptibility genes intype 1 diabetes. Diabetes. 2009; 58(6): 1403-10. Epub 2009/03/03.
77. Burgess DJ. Genomics: Getting personal and regional. Naturereviews Genetics. 2011; 12(11): 744. Epub 2011/10/05.
78. Pearson TA, Manolio TA. How to interpret a genome-wideassociation study. JAMA. 2008; 299(11): 1335-44. Epub2008/03/20.
79. Gunter C. Human genomics: Known and unknown. Nature reviewsGenetics. 2011; 12(8): 520-1. Epub 2011/07/13.
80. Connolly SB, Sadlier D, Kieran NE, Doran P, Brady HR. Transcriptome profiling and the pathogenesis of diabeticcomplications. J Am Soc Nephrol. 2003; 14(8 Suppl 3): S279-83. Epub 2003/07/23.
81. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nature methods. 2008; 5(7): 621-8. Epub 2008/06/03.
82. Schmid H, Boucherot A, Yasuda Y, et al. Modular activation ofnuclear factor-kappaB transcriptional programs in human diabeticnephropathy. Diabetes. 2006; 55(11): 2993-3003. Epub2006/10/27.
83. Ortiz A, Lorz C, Egido J. The Fas ligand/Fas system in renalinjury. Nephrol Dial Transplant. 1999; 14(8): 1831-4. Epub1999/08/26.
84. Gonzalez-Cuadrado S, Lorz C, Garcia del Moral R, et al. Agonisticanti-Fas antibodies induce glomerular cell apoptosis in mice invivo. Kidney Int. 1997; 51(6): 1739-46. Epub 1997/06/01.
85. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4)and 2 (DR5) signal FADD-dependent apoptosis and activate NFkappaB. Immunity. 1997; 7(6): 831-6. Epub 1998/01/16.
86. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: anovel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2): 309-19. Epub 1997/04/18.
87. Lorz C, Benito-Martin A, Boucherot A, U, et al. The death ligandTRAIL in diabetic nephropathy. J Am Soc Nephrol. 2008; 19(5):904-14. Epub 2008/02/22.
88. de Borst MH, Benigni A, Remuzzi G. Primer: strategies foridentifying genes involved in renal disease. Nature clinical practiceNephrology. 2008; 4(5): 265-76. Epub 2008/03/28.
89. Connor SC, Hansen MK, Corner A, Smith RF, Ryan TE. Integration of metabolomics and transcriptomics data to aidbiomarker discovery in type 2 diabetes. Molecular bioSystems.2010; 6(5): 909-21. Epub 2010/06/23.
90. Martini S, Eichinger F, Nair V, Kretzler M. Defining humandiabetic nephropathy on the molecular level: integration oftranscriptomic profiles with biological knowledge. Reviews inendocrine & metabolic disorders. 2008; 9(4): 267-74. Epub2008/08/16.
91. Dressler GR. Epigenetics, development, and the kidney. J Am SocNephrol. 2008; 19(11): 2060-7. Epub 2008/08/22.
92. Bonasio R, Tu S, Reinberg D. Molecular signals of epigeneticstates. Science. 2010; 330(6004): 612-6. Epub 2010/10/30.
93. Villeneuve LM, Natarajan R. The role of epigenetics in thepathology of diabetic complications. Am J Physiol Renal Physiol.2010; 299(1): F14-25. Epub 2010/05/14.
94. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigeneticphenomena linked to diabetic complications. Nature reviewsEndocrinology. 2010; 6(12): 665-75. Epub 2010/11/04.
95. Reddy MA, Natarajan R. Epigenetics in diabetic kidney disease. JAm Soc Nephrol. 2011; 22(12): 2182-5. Epub 2011/10/25.
96. Kuroda A, Rauch TA, Todorov I, et al. Insulin gene expression isregulated by DNA methylation. PLoS One. 2009; 4(9): e6953. Epub 2009/09/11.
97. Park JH, Stoffers DA, Nicholls RD, Simmons RA. Development oftype 2 diabetes following intrauterine growth retardation in rats isassociated with progressive epigenetic silencing of Pdx1. J ClinInvest. 2008; 118(6): 2316-24. Epub 2008/05/10.
98. Morgan HD, Sutherland HG, Martin DI, Whitelaw E. Epigeneticinheritance at the agouti locus in the mouse. Nature genetics. 1999;23(3): 314-8. Epub 1999/11/05.
99. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in12 body fluids. Clinical chemistry. 2010; 56(11): 1733-41. Epub2010/09/18.
100. Patnaik SK, Mallick R, Yendamuri S. Detection of microRNAs indried serum blots. Anal Biochem. 2010; 407(1): 147-9. Epub2010/08/11.
101. Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specificdeletion of dicer alters cytoskeletal dynamics and causesglomerular disease. J Am Soc Nephrol. 2008; 19(11): 2150-8. Epub2008/09/09.
102. Shi S, Yu L, Chiu C, et al. Podocyte-selective deletion of dicerinduces proteinuria and glomerulosclerosis. J Am Soc Nephrol.2008; 19(11): 2159-69. Epub 2008/09/09.
103. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetickidney glomeruli and its function in TGF-beta-induced collagenexpression via inhibition of E-box repressors. Proc Natl Acad SciU S A. 2007; 104(9): 3432-7. Epub 2007/03/16.
104. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D. Lossof MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol. 2010; 21(3): 438-47. Epub 2010/01/09.
105. Wang B, Herman-Edelstein M, Koh P, et al. E-cadherin expressionis regulated by miR-192/215 by a mechanism that is independent ofthe profibrotic effects of transforming growth factor-beta. Diabetes.2010; 59(7): 1794-802. Epub 2010/04/16.
106. Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wideassociation studies for common human diseases. Nature reviewsGenetics. 2011; 12(8): 529-41. Epub 2011/07/13.
107. Fliser D, Novak J, Thongboonkerd V, et al. Advances in urinaryproteome analysis and biomarker discovery. J Am Soc Nephrol.2007; 18(4): 1057-71. Epub 2007/03/03.
108. Otu HH, Can H, Spentzos D, et al. Prediction of diabeticnephropathy using urine proteomic profiling 10 years prior todevelopment of nephropathy. Diabetes Care. 2007; 30(3): 638-43. Epub 2007/03/01.
109. Rossing K, Mischak H, Dakna M, et al. Urinary proteomics indiabetes and CKD. J Am Soc Nephrol. 2008; 19(7): 1283-90. Epub2008/05/02.
110. Alkhalaf A, Zurbig P, Bakker SJ, et al. Multicentric validation ofproteomic biomarkers in urine specific for diabetic nephropathy. PLoS One. 2010; 5(10): e13421. Epub 2010/10/27.
111. Merchant ML, Perkins BA, Boratyn GM, et al. Urinary peptidomemay predict renal function decline in type 1 diabetes andmicroalbuminuria. J Am Soc Nephrol. 2009; 20(9): 2065-74. Epub2009/08/01.
112. Ben Ameur R, Molina L, Bolvin C, et al. Proteomic approaches fordiscovering biomarkers of diabetic nephropathy. Nephrol DialTransplant. 2010; 25(9): 2866-75. Epub 2010/05/18.
113. Muller GA, Muller CA, Dihazi H. Clinical proteomics--on the longway from bench to bedside? Nephrol Dial Transplant. 2007; 22(5):1297-300. Epub 2007/02/15.
114. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functionalanalysis of the yeast genome. Trends Biotechnol. 1998; 16(9): 373-8. Epub 1998/09/23.
115. Barderas MG, Laborde CM, Posada M, et al. Metabolomicprofiling for identification of novel potential biomarkers incardiovascular diseases. J Biomed Biotechnol. 2011; 2011: 790132. Epub 2011/01/29.
116. McKillop AM, Flatt PR. Emerging applications of metabolomicand genomic profiling in diabetic clinical medicine. Diabetes Care.2011; 34(12): 2624-30. Epub 2011/11/24.
117. Wang JH, Byun J, Pennathur S. Analytical approaches tometabolomics and applications to systems biology. Semin Nephrol.2010; 30(5): 500-11. Epub 2010/11/04.
118. Zhang H, Saha J, Byun J, et al. Rosiglitazone reduces renal andplasma markers of oxidative injury and reverses urinary metaboliteabnormalities in the amelioration of diabetic nephropathy. Am JPhysiol Renal Physiol. 2008; 295(4): F1071-81. Epub 2008/08/01.
119. Han LD, Xia JF, Liang QL, et al. Plasma esterified and nonesterifiedfatty acids metabolic profiling using gaschromatography-mass spectrometry and its application in the studyof diabetic mellitus and diabetic nephropathy. Anal Chim Acta.2011; 689(1): 85-91. Epub 2011/02/23.
120. Mogensen CE, Christensen CK, Vittinghus E. The stages indiabetic renal disease. With emphasis on the stage of incipientdiabetic nephropathy. Diabetes. 1983; 32 Suppl 2: 64-78. Epub1983/05/01.
121. Wishart DS, Tzur D, Knox C, et al. HMDB: the HumanMetabolome Database. Nucleic acids research. 2007; 35(Databaseissue): D521-6. Epub 2007/01/05.
122. Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase forthe human metabolome. Nucleic acids research. 2009; 37(Databaseissue): D603-10. Epub 2008/10/28.
123. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulindependentdiabetics. Diabet Med. 1984; 1(1): 17-9. Epub1984/05/01.
124. Mussap M, Dalla Vestra M, Fioretto P, et al. Cystatin C is a moresensitive marker than creatinine for the estimation of GFR in type 2diabetic patients. Kidney Int. 2002; 61(4): 1453-61. Epub2002/03/29.
125. Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimatesof renal function: searching for a better measure of kidney functionin diabetic patients. Clinical chemistry. 2007; 53(3): 480-8. Epub2007/01/30.
126. Rigalleau V, Beauvieux MC, Le Moigne F, et al. Cystatin Cimproves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes& metabolism. 2008; 34(5): 482-9. Epub 2008/08/16.
127. Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuriaand the risk for early progressive renal function decline in type 1diabetes. J Am Soc Nephrol. 2007; 18(4): 1353-61. Epub2007/03/03.
128. Koshimura J, Fujita H, Narita T, et al. Urinary adiponectinexcretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun. 2004; 316(1): 165-9. Epub2004/03/09.
129. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetespatients with microalbuminuria. Metabolism. 2001; 50(10): 1193-6. Epub 2001/10/05.